stockrowGSK PLC Sponsored ADR
GSK Healthcare Drug Manufacturers General
GSK PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $43.1 billion, up 7.44% from fiscal 2024.
- Revenue
- +3.75%
- EPS
- −14.7%
- Free cash flow
- +62.4%
- Total debt
- +33.2%
Quarter to September 2026, against a year earlier
Follow GSK
Alert me
GSK PLC Sponsored ADR (GSK) EV/FCF
As of 5 November 2026, GSK PLC Sponsored ADR (GSK) trades at a EV/FCF of 14.6×. Over the past ten years it has ranged from −7.5× (April 2016) to 50.6× (February 2016); the current reading is higher than 26% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 18.3× | 2.95% |
| FY2024 | 17.8× | 7.45% |
| FY2023 | 16.5× | 28.94% |
| FY2022 | 12.8× | (23.80%) |
| FY2021 | 16.8× | 37.73% |
| FY2020 | 12.2× | (33.25%) |
| FY2019 | 18.3× | 39.85% |
| FY2018 | 13.1× | (20.56%) |
| FY2017 | 16.5× | (10.59%) |
| FY2016 | 18.4× | (62.33%) |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 14.1× | (14.13%) |
| Jun 2026 | 16.4× | (18.72%) |
| Mar 2026 | 20.2× | 10.30% |
| Dec 2025 | 18.3× | 10.72% |
| 43 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| SNY Sanofi compare | 7.5× |
| GSK GSK PLC Sponsored ADR | 14.6× |
| GILD Gilead Sciences, Inc. compare | 16.5× |
| BMY Bristol Myers Squibb Company compare | 17.2× |
| PFE Pfizer Inc. compare | 19.9× |
| BIIB Biogen Inc. compare | 24.9× |
| NVO Novo Nordisk A/S compare | 25.4× |
| AMGN Amgen Inc. compare | 31.8× |
| AZN AstraZeneca PLC compare | 49.5× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on GSK
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement